title: [Efficacy and safety of sublingual immunotherapy with house dust mite extract in poly allergen sensitized children with allergic rhinitis].
abstract: OBJECTIVE
  To compare the efficacy of sublingual immunotherapy (SLIT) with standardized house dust mite extract in mono sensitized and polysensitized children with allergic rhinitis.
  
  
  METHODS
  One hundred and fifty-seven children who were sensitized to house dust mites and treated with SLIT for house dust mites for at least 1 year were studied. The monoallergen sensitized group included patients who were sensitized to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae (n=92). The polyallergen sensitized group included patients who were simultaneously sensitized to house dust mites and other allergens (n = 65). A standardized extract of house dust mites was used for immunotherapy. Antiallergic medication and the total nasal symptom score (TNSS) were evaluated before and 1 year after SLIT.
  
  
  RESULTS
  One hundred and twenty-five children completed 1-year SLIT. The TNSS improved significantly after SLIT in both groups, with monoallergen sensitized group 11.42 +/- 1.60 vs 3.55 +/- 1.57 (t=30.03, P<0.01), and polyallergen sensitized group 11.54 +/- 1.55 vs 3.23 +/- 1.56 (t=27.76, P< 0.01). But the change in the TNSS did not differ significantly between the groups (TNSS change, 7.94 +/- 2.24 vs 8.32 +/- 2.18, P>0.05). The AMSs were decreased significantly after SLIT in both groups, with monoallergen sensitized group 1.62 +/- 0.44 vs 0.56 +/- 0.37 (t=15.01, P<0.01), and polyallergen sensitized group 1.63 +/- 0.43 vs 0.50 +/- 0.40 (t=13.49, P<0.01). But the AMSs improvement did not differ significantly between the two groups(AMSs change 1.03 +/- 0.58 vs 1.13 +/- 0.61, P>0.05).
  
  
  CONCLUSIONS
  In polysensitized allergic rhinitis patients, SLIT for D pteronyssinus and/or D farinae produced improvements in both nasal symptoms and rescue medication scores comparable to those in mono sensitized patients. SLIT for D pteronyssinus and/or D farinae should be considered in polysensitized allergic rhinitis patients.
authors.affiliation: Department of Otolaryngology,Guangzhou Women and Children Medical Central, Guangzhou, 510623, China.
authors.forename: Lifeng
authors.initials: L
authors.lastname: Zhou
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
authors.forename: Yanqiu
authors.initials: Y
authors.lastname: Chen
authors.forename: Renzhong
authors.initials: R
authors.lastname: Luo
authors.forename: Jia
authors.initials: J
authors.lastname: Tao
authors.forename: Mingrong
authors.initials: M
authors.lastname: Nie
authors.forename: Bixia
authors.initials: B
authors.lastname: Liu
authors.forename: Yuyun
authors.initials: Y
authors.lastname: Li
mesh_terms: D000286:Administration, Sublingual; D000293:Adolescent; D000818:Animals; D039741:Antigens, Dermatophagoides / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D001249:Asthma / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D040001:Dermatophagoides farinae / Q000276:immunology; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D065631:Rhinitis, Allergic; D012221:Rhinitis, Allergic, Perennial / Q000628:therapy*
chemical_list: D039741:Antigens, Dermatophagoides